Lifecore Biomedical, INC \de\ 8-K filings

Lifecore Biomedical reported a decrease in revenue and gross profit for Q2 2026 compared to the prior year, while reaffirming its full-year financial guidance and highlighting new business wins.

Lifecore Biomedical announced the redemption of all outstanding Series A Redeemable Convertible Preferred Stock, totaling approximately $52.1 million, with a payment deadline of December 28, 2026.

Lifecore Biomedical stockholders approved the 2026 Stock Incentive Plan and elected nine directors at the annual meeting.

Lifecore Biomedical reported a 34% revenue decrease in Q1 2026 compared to the prior year, alongside significant operating expense reductions and reaffirmed full-year guidance.

Lifecore Biomedical reported strong financial results for the fourth quarter and transition period ended December 31, 2025, surpassing revenue guidance and significantly improving margins.

Lifecore Biomedical, Inc. announced a change in its fiscal year to align with the calendar year, impacting its 2026 Annual Meeting and shareholder nomination deadlines.

Lifecore Biomedical, Inc. has adopted an Incentive Bonus Plan for executive officers and employees, effective January 14, 2026, linking cash payments to performance targets.

Lifecore Biomedical, Inc. outlines a strategic plan to achieve sustainable growth, targeting 12% revenue CAGR and over 25% Adjusted EBITDA margins in the mid-term, driven by capacity utilization and new business.

Lifecore Biomedical, Inc. announced a 26% increase in revenue for the three months ended September 30, 2025, alongside significant operational efficiencies and new program signings.

Lifecore Biomedical, Inc. announced the successful election of all director nominees, ratification of KPMG LLP as its auditor, and approval of executive compensation at its 2025 annual meeting.

Lifecore Biomedical, Inc. has approved a new cash incentive plan for its executive officers, aligning compensation with financial and business goals for the CY 2025 Transition Period.

Lifecore Biomedical, Inc. has appointed KPMG LLP as its new independent registered public accounting firm, replacing BDO USA, P.C., effective August 12, 2025.

Lifecore Biomedical, Inc. outlines an aggressive growth strategy, targeting over 12% revenue CAGR and 25%+ Adjusted EBITDA margins in the mid-term, driven by expanded capacity and a robust pipeline.

Lifecore Biomedical reported fiscal year 2025 revenue of $128.9 million, meeting full-year guidance, and announced a shift to a calendar year fiscal end, alongside new program signings and operational efficiencies.

Lifecore Biomedical, Inc. has approved its 2026 Bonus Plan, linking executive cash incentives primarily to Adjusted EBITDA and development revenue performance.

Lifecore Biomedical's Board of Directors has increased the number of shares available under its Equity Inducement Plan by 750,000 shares.

Lifecore Biomedical stockholders approved the issuance of common stock underlying Series A Preferred Stock at a Special Meeting held on April 10, 2025.

Lifecore Biomedical announces its Q3 fiscal 2025 financial results, highlighting revenue of $35.2 million and reaffirming its full-year revenue and Adjusted EBITDA guidance.

Lifecore Biomedical is holding a special stockholder meeting to vote on a proposal to remove a cap on the conversion of its Series A Convertible Preferred Stock to common stock.

Lifecore Biomedical has sold a 10-head isolator filler for $17 million, strengthening its financial position and focusing on its recently installed 5-head filler.

Lifecore Biomedical announced positive second quarter fiscal 2025 results, highlighted by increased revenues, new customer agreements, and a strengthened balance sheet.

Lifecore Biomedical has amended and extended its revolving credit facility with BMO, securing a three-year term extension, simplified terms, and reduced interest rates.

Lifecore Biomedical presented its strategy for sustainable growth, targeting a 12%+ revenue CAGR and 25%+ adjusted EBITDA margins in the mid-term.

Lifecore Biomedical held its 2024 Annual Meeting of Stockholders, electing five directors, ratifying its auditor, and approving executive compensation.

Lifecore Biomedical closed a $24.3 million private placement and reported first quarter fiscal 2025 financial results, highlighting increased capacity and new customer agreements.

Lifecore Biomedical has announced the departure of two directors and set the date for its 2024 annual meeting of stockholders.

Lifecore Biomedical has regained compliance with Nasdaq listing rules after filing overdue financial reports and holding its annual shareholder meeting.

Lifecore Biomedical has appointed Ryan Lake as its new Chief Financial Officer, effective September 3, 2024, succeeding John Morberg who is stepping down.

Lifecore Biomedical announced a 24.2% increase in revenue for fiscal year 2024, reaching $128.3 million, alongside significant improvements in gross profit and adjusted EBITDA.

Lifecore Biomedical's stockholders approved amendments to declassify the board of directors and increase the number of authorized shares at the 2023 Annual Meeting.